John G Ullman & Associates Inc. Sells 80 Shares of United Therapeutics Co. (NASDAQ:UTHR)

John G Ullman & Associates Inc. trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,355 shares of the biotechnology company’s stock after selling 80 shares during the quarter. John G Ullman & Associates Inc.’s holdings in United Therapeutics were worth $2,595,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Milestone Asset Management LLC increased its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 1,037 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after purchasing an additional 789 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after purchasing an additional 50,291 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Finally, Burney Co. grew its position in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after acquiring an additional 12,705 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on UTHR. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $319.96 on Friday. The firm has a market capitalization of $14.28 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.57. The stock has a 50 day moving average price of $359.65 and a 200 day moving average price of $360.71. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business earned $4.36 earnings per share. Analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares of the company’s stock, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 124,164 shares of company stock worth $45,278,893. Company insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.